
    
      The purpose of this first in human study is to determine the safety and pharmacokinetics of
      KX2-391 in patients with solid tumors and lymphoma, who are refractory to conventional cancer
      treatments. In addition, pharmacodynamics will be evaluated using biomarkers in peripheral
      blood mononuclear cells and in tissue biopsy samples.
    
  